LOCOID- hydrocortisone butyrate cream Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

locoid- hydrocortisone butyrate cream

bausch health us, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g - locoid (hydrocortisone butyrate) cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. none.

LOCOID- hydrocortisone butyrate solution Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

locoid- hydrocortisone butyrate solution

bausch health us, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - locoid (hydrocortisone butyrate) solution, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis. none.

LOCOID LIPOCREAM- hydrocortisone butyrate cream Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

locoid lipocream- hydrocortisone butyrate cream

bausch health us, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g - locoid lipocream is indicated for: none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. therefore, locoid lipocream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate cream (25 g). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses of 0.6, 1.8, and 5.4 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats during gestation days 6 - 17. in the

Locoid Scalp lotion Cutaneous Solution 1mg/ml Malta - angļu - Medicines Authority

locoid scalp lotion cutaneous solution 1mg/ml

leo pharma a/s industriparken 55, 2750-dk ballerup, denmark - hydrocortisone butyrate - cutaneous solution - hydrocortisone butyrate 1 mg/g - corticosteroids, dermatological preparations

Locoid Cream Cream 1mg/g Malta - angļu - Medicines Authority

locoid cream cream 1mg/g

leo pharma a/s industriparken 55, 2750-dk ballerup, denmark - hydrocortisone butyrate - cream - hydrocortisone butyrate 1 milligram(s)/gram - corticosteroids, dermatological preparations

LOCOID- hydrocortisone butyrate lotion Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

locoid- hydrocortisone butyrate lotion

bausch health us, llc - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - locoid® lotion is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. none. pregnancy   risk summary there are no controlled or large-scale epidemiologic studies with locoid lotion in pregnant women, and available data on hydrocortisone butyrate use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, when administered subcutaneously or topically to pregnant rats, rabbits, and mice, hydrocortisone butyrate induced adverse reproductive and developmental outcomes, including abortion, fetal death, malformation, delayed ossification, decrease in fetal weight, and delay in sexual maturation (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposure of hydrocortisone butyrate observed in animal studies and the systemic exposure that would be expected in humans after topical use of lo

Locoid Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

locoid

link pharmaceuticals ltd - hydrocortisone butyrate 0.1%;   - scalp lotion - 0.1 % - active: hydrocortisone butyrate 0.1%   excipient: citric acid glycerol isopropyl alcohol povidone purified water sodium citrate

Locoid Crelo Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

locoid crelo

link pharmaceuticals ltd - hydrocortisone butyrate 0.1%{relative} (1.5% overage);   - topical emulsion - 0.1% w/w - active: hydrocortisone butyrate 0.1%{relative} (1.5% overage)   excipient: borage oil butyl hydroxybenzoate butylated hydroxytoluene cetomacrogol cetostearyl alcohol citric acid hard paraffin propyl hydroxybenzoate propylene glycol purified water sodium citrate dihydrate white soft paraffin

Locoid Lipocream Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

locoid lipocream

link pharmaceuticals ltd - hydrocortisone butyrate 0.1%;   - topical cream - 0.1 % - active: hydrocortisone butyrate 0.1%   excipient: benzyl alcohol cetomacrogol 1000 cetostearyl alcohol citric acid light liquid paraffin propyl hydroxybenzoate purified water sodium citrate white soft paraffin - the treatment of conditions responsive to topical corticosteroids, e.g. eczema, dermatitis and psoriasis.

Locoid Crelo 0.1% Malta - angļu - Medicines Authority

locoid crelo 0.1%

astellas pharma europe b.v. - hydrocortisone butyrate 1 mg/g - cutaneous emulsion